This is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer.
Breast cancer (BC) is the most common solid tumor in women, with the triple negative subtype associated with poorer overall survival and a higher probability of cancer recurrence.
Given the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress, the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summit has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint, DDR inhibitor, ADC and other novel agents.
This is the industry's definitive conference specifically dedicated to advancing the development of both monotherapy and combinatorial
therapies to improve the current standard of care for patients with TNBC.
Join leading experts from CytoDyn, Zenith Epigenetics, Oncorus, University of Pittsburgh and more who are identifying specific molecular targets, such as immune checkpoint modulators, intra-nuclear targets, intracellular targets, and cell surface targets, to limit the progression and metastasis of this invasive tumor and improve patient outcomes.
Whether you are developing a TROP2-ADC, a PARP inhibitor, a viral immunotherapy or a cancer vaccine for treating TNBC, this dedicated digital meeting is your opportunity to discuss novel, cutting edge targeted therapies in TNBC and get a full picture of the clinical landscape.
Group discounts and early booking rates are available. Please visit the website for full pricing information.